Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21986932 | 1.00 | MAPT (0.32) | MAPTGAA | |
| SCHEMBL21958284 | 1.00 | MAPT (0.32) | MAPTGAA | |
| SCHEMBL21058321 | 0.86 | MAPT (0.34) | MAPTGAA | |
| SCHEMBL28912802 | 0.86 | MAPT (0.34) | MAPTGAA | |
| SCHEMBL21058323 | 0.82 | MAPT (0.32) | MAPTGAA | |
| SCHEMBL28562895 | 0.82 | MAPT (0.32) | MAPTGAA | |
| SCHEMBL17925541 | 0.81 | HDAC1 (0.39) | — | |
| SCHEMBL21058306 | 0.80 | TSHR (0.33) | MAPT | |
| SCHEMBL21058307 | 0.77 | EGLN1 (0.30) | — | |
| SCHEMBL21058304 | 0.77 | MAPT (0.31) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931197-B1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-109952305-B | Piperazino heteroaryl derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3931197-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | F. Hoffmann-La Roche AG (CH) | 2022-01-05 | — | — | EP | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200181156-A1 | CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3458455-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| WO-2018011160-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011162-A1 | CARBOXY 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017198744-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181156-A1 | CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | TPMT, CYP3A5, QDPR | MAPT 3103/4885GAA 2820/4885 |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | MAPT 3648/4885GAA 3730/4885 |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HCCS, CYP2S1, CYP3A5 | MAPT 3541/4885GAA 2860/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | MAPT 2652/4885GAA 2710/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | MAPT 3266/4885GAA 2782/4885 |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | MAPT 2652/4885GAA 2710/4885 |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HAVCR2, CYP3A43, CYP3A5 | MAPT 3624/4885GAA 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.